Tisbury Pharmaceuticals is a Boston-based pharmaceutical company focused on the discovery, development and commercialization of therapies to treat glaucoma. Its lead clinical candidate, R-801, markedly decreases intraocular pressure by increasing intraocular fluid egress through the trabecular meshwork. The company intends to use the $32M Series A proceeds to initiate a clinical program for R-801. Tisbury spun out from Radikal Therapeutics and was founded by Andrew L. Salzman, MD, who serves as chairman. Gary Sternberg, MD, MBA, the newly appointed CEO and former Chief Business Officer of Eleven Biotherapeutics, will lead the clinical development out of the Boston office. The Series A was led by OrbiMed Israel, Clarus and HealthCap, with participation from Pontifax, and the financing coincided with multiple board appointments.

Total raised

$32M

Funding rounds

1

Latest round

Series A

Latest activity

Jun 2017